Servier said sevasemten failed to show statistically significant benefit in a pivotal Phase 3 study for Becker muscular dystrophy, dealing another blow to a muscular dystrophy program purchased in a $1.5 billion deal. According to the report, while the drug met goals in an earlier Phase 2 test in Becker muscular dystrophy, new results in the larger pivotal cohort did not align with prior findings. Servier said it would conduct a comprehensive analysis of the GRAND CANYON dataset and relevant earlier study data. The outcome highlights the high-risk profile of late-stage neuromuscular development and may force the company and partners to reconsider translational assumptions for follow-on work.